Compare ADPT & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | NATL |
|---|---|---|
| Founded | 2009 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2019 | N/A |
| Metric | ADPT | NATL |
|---|---|---|
| Price | $15.41 | $38.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $16.60 | ★ $42.75 |
| AVG Volume (30 Days) | ★ 3.0M | 449.1K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.74 |
| Revenue | $252,754,000.00 | ★ $4,322,000,000.00 |
| Revenue This Year | $50.81 | $2.83 |
| Revenue Next Year | $1.17 | $3.96 |
| P/E Ratio | ★ N/A | $22.24 |
| Revenue Growth | ★ 42.57 | 0.63 |
| 52 Week Low | $5.81 | $22.30 |
| 52 Week High | $20.76 | $42.23 |
| Indicator | ADPT | NATL |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 62.03 |
| Support Level | $14.58 | $36.12 |
| Resistance Level | $16.26 | $37.61 |
| Average True Range (ATR) | 1.13 | 0.94 |
| MACD | -0.36 | 0.32 |
| Stochastic Oscillator | 13.75 | 86.58 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.